What Is Claimed Is:

- 1. An isolated antibody which binds to the Map10 protein from S. aureus.
- An antibody according to Claim 1, wherein said antibody prevents S. aureus infection in a human or animal.
- An antibody according to Claim 1, wherein said antibody inhibits binding of staphylococcal bacteria to eukaryotic cells.
- 4. An antibody according to Claim 1, wherein said antibody is suitable for parenteral, oral, intranasal, subcutaneous, aerosolized or intravenous administration in a human or animal.
- An antibody according to Claim 1 wherein the antibody is a monoclonal antibody.
- An antibody according to Claim 5 wherein the monoclonal antibody is of a type selected from the group consisting of chimeric, humanized and human monoclonal antibodies

- An antibody according to Claim 5 wherein the antibody is a single chain monoclonal antibody.
- 8. An antibody according to Claim 1 which comprises a antibody fragment having the same binding specificity of an antibody which binds to the *S. aureus* MAP protein.
- An antibody according to Claim 1 having a variable light sequence according to SEQ ID NO:4.
- An antibody according to Claim 1 having a variable light sequence encoded by a nucleic acid sequence according to SEQ ID NO:3 or degenerates thereof.
- An antibody according to Claim 1 having a variable heavy sequence according to SEQ ID NO:6.
- An antibody according to Claim 1 having a variable light sequence encoded by a nucleic acid sequence according to SEQ ID NO:5 or degenerates thereof.
- An antibody according to Claim 1 wherein the antibody is a polyclonal antibody.
- 14. Isolated antisera containing an antibody according to Claim 1.

- A diagnostic kit comprising an antibody according to Claim 1 and means for detecting binding by that antibody.
- A diagnostic kit according to Claim 15 wherein said means for detecting binding comprises a detectable label that is linked to said antibody.
- 17. A method of diagnosing an infection of *S. aureus* comprising adding an antibody according to Claim 1 to a sample suspected of being infected with *S. aureus*, and determining if antibodies have bound to the sample.
- 18. A pharmaceutical composition for treating or preventing an infection of S. aureus comprising an effective amount of the antibody of Claim 1 and a pharmaceutically acceptable vehicle, carrier or excipient.
- 19. A method of treating or preventing an infection of S. aureus comprising administering to a human or animal patient an effective amount of an antibody according to Claim 1.
- 20. A method of inducing an immunological response comprising administering to a human or animal an isolated *S. aureus* Map10 protein.

- 21. A method of identifying antibodies to the Map10 protein comprising adding an isolated Map10 protein to a sample suspected of containing anti-MAP antibodies, and determining if antibodies have bound to the added Map10 protein.
- 22. An isolated antibody which binds to the Map10 protein from S. aureus.
- 23. An isolated antibody according to Claim 1 that has the ability to bind to the amino acid sequence of SEQ ID NO:2.
- 24. An isolated antibody according to Claim 1 that has the ability to bind to an amino acid sequence coded by the nucleic acid sequence of SEQ ID NO:1 or degenerates thereof.
- An isolated antibody having a variable light sequence according to SEQ ID NO:4.
- An isolated antibody having a variable heavy sequence according to SEQ ID NO:6.
- 27. An isolated S. aureus Map10 protein.

- 28. An isolated protein according to Claim 27 having an amino acid sequence according to SEQ ID NO:2.
- 29. An isolated protein according to Claim 27 having an amino acid sequence encoded by a nucleic acid sequence according to SEQ ID NO:1 or degenerates thereof.